Several studies have shown that chronic GVHD (cGVHD) is more frequent in patients receiving transplants from PBSC than in those receiving BM. In the setting of PBSC-unrelated transplants, the addition of anti-T-cell globulin (ATG) has shown a significant decrease in incidence/severity of cGVHD, without an increase in relapses or infections. However, no prospective data are yet available in the sibling setting. We retrospectively analyzed the effects of intensification of standard GVHD prophylaxis (CsA þ MTX) by the addition of low-dose ATG in 245 patients receiving a transplant from HLA-identical sibling. From 1996 to 2001, patients received PBSC as the preferred source (group 2), and then ATG was added before transplant (group 3) because of a high cGVHD rate. Patients receiving BM in the same time period were analyzed as a control group (group 1). The incidence of grade IIIÀIV acute GVHD and cGVHD was not significantly different in the three groups, but extensive cGVHD was highest in group 2 (38%) compared with group 3 (21%) or group 1 (28%; P ¼ 0.03). OS, TRM and time to relapse/progression were similar in the three groups. Our analysis shows that adding ATG to PBSC sibling allogeneic transplants can lower cGVHD, without an increase of relapse. Further prospective studies are needed to confirm these findings.
INTRODUCTION
The first reports of allogeneic PBSC transplants appeared in 1995. 1 --3 Since then, their use has grown so rapidly that already by 2001 they had become the preferred source of hematopoietic stem cells. 4 Many studies, 5 --11 including those with extended observation of the early series 12 --15 and two meta-analyses, 16 ,17 conclusively showed that PBSC transplants are associated with high rates of chronic GVHD (cGVHD), especially of the extensive type, with a substantial impact on quality of life. 18, 19 However, the true benefits of cGVHD on relapse and more generally on transplant outcome are still controversial. Recently, some authors have compared the value of PBSC with BM transplants, and concluded that additional studies with longer follow-up are necessary to establish which source will produce the best OS or disease-free survival. 20 On the other hand, Pidala et al., 21 in their decision analysis paper, demonstrated with a multistate model that PBSC transplants are superior to BM and lead to a gain in life expectancy in all the conditions that are associated with a relapse risk greater than 5%.
Extensive cGVHD remains a problem, and several strategies can be applied to minimize it; the majority of transplants performed with PBSC relied on the classical combination of a calcineurin inhibitor---CsA or tacrolimus---and MTX, or, more recently, in reduced intensity conditioning (RIC) regimens, on CsA or tacrolimus and mycophenolate mofetil.
One way to intensify GVHD prophylaxis without hampering the beneficial anti-leukemic effect associated with GVHD is to use anti-T-cell globulins (ATGs). The results from a recent, prospective, randomized study in the unrelated setting, 22 with more than 80% of transplants being from PBSC, confirmed this hypothesis. The authors showed that the addition of ATG (ATG-Fresenius (ATG-F), 60 mg/kg as total dose) resulted in a lower incidence of acute grade III --IV GVHD (11.7% vs 24.5%) and a lower 2-year incidence of cGVHD (12.2% vs 42.6%), without significant effects on relapse. However, survival, TRM and mortality from infections were not different. To our knowledge, no phase III studies are yet reported in the sibling setting. Here, we describe 245 consecutive adult patients with hematological malignancies receiving a fully HLA-identical sibling transplant and the same GVHD prophylaxis, transplanted between 1996 and 2006. From 1996 to 2001, the preferred stem cell source was PBSC (group 2); after that date, because of the high incidence of cGVHD, 23 ATG-F was added (group 3) in the conditioning regimen; patients receiving BM, because of donor ineligibility for PBSC collection, were analyzed as the control group (group 1).
PATIENTS AND METHODS

Donors and patients
From 1996 to 2006, 245 consecutive sibling transplants have been performed in adults with hematological malignancies at the Department of Hematology, 'L and A Seràgnoli', St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. Written informed consent was obtained from each patient and donor. The donors were HLA-identical siblings; PBSC donors received 5 mg/kg/day of lenograstim with s.c. injections twice a day for 5 days and underwent apheresis on the fifth day. The target of apheresis was 43 Â 10 6 /CD34 þ cells/kg and the product was cryopreserved until transplant. BM donors underwent marrow harvesting under general anesthesia and the product was infused immediately thereafter.
From 1996 to 2001, the first choice of hematopoietic stem cell for HLAidentical sibling transplants was PBSC; then, starting in 2002, due to a high incidence of cGVHD, ATG-F (Bad Homburg, D) was added to the preparative regimen. If the donor was ineligible for PBSC collection (42) or refused the procedure (10), BM was used instead. The reasons for ineligibility for PBSC collection were the following: age o18 years or 470 years (3), lack of peripheral vein access (5), infection or carrier status for hepatitis B virus and/or hepatitis C virus (14), presence of a diagnosed or strongly suspected autoimmune disease (9), previous diagnosis of a neoplasia (3), family or personal history of a thrombotic event (3), a-thalassemia (1), lactating women (2) and others (2).
Patients were subdivided into three groups: group 1 was represented by patients receiving BM (52) as source of stem cells, group 2 by those receiving PBSC (146) and group 3 by those receiving PBSC and ATG-F (47). All patients received GVHD prophylaxis with CsA and short-term MTX (days 1, 3, 6 and 11 with 15, 10, 10 and10 mg/m 2 for myeloablative (MA) transplants and days 1, 3 and 6 with 10, 8 and 8 mg/m 2 for reduced intensity transplants (RIC)). In seven cases of RIC transplant, mycophenolate mofetil was used instead of MTX. CsA was started i.v. from day --1 at 3 mg/ kg (MA transplants) and from day --6 at 1 mg/kg and then to 2 mg/kg from day --2 (RIC transplants) given in a 16-h infusion and then changed orally when oral feeding was possible. Doses were adjusted to maintain levels of CsA between 200 and 300 ng/mL. Tapering of CsA was started in the absence of cGVHD at 4 --8 months, depending on the phase of disease at transplant, with the aim to discontinue the drug by 1 year. If cGVHD was present, CsA was continued and/or other agents were introduced as necessary. The main clinical and pretransplant characteristics of the study population are shown in Table 1 .
Patients with CML in first chronic phase, ALL and AML in first CR and CR of lymphomas were considered as early phase; all the remaining were considered as advanced phase. Conditioning regimens are also summarized in Table 1 . MA preparative regimens were unfractionated TBI (800 cGy from a linear accelerator or 1000 cGy from a cobalt 60 source, both at lowdose rate) and CY 120 mg/kg or BU (16 mg/kg oral dose or 12.8 mg/kg if administered i.v.) given mainly with CY 120 mg/kg. The RIC consisted of thiotepa 10 mg/kg, fludarabine 60 mg/m 2 and CY 60 mg/kg, or melphalan 140 mg/m 2 and fludarabine 120 mg/m 2 . ATG-F was given from day À6 to day À2, at a daily dose of 3--6 mg/kg (total dose 15--30 mg/kg); the infusion time was 6--12 h.
Acute GVHD (aGVHD) and cGVHD diagnosis and grading were performed by the classical criteria. Patients were considered at risk of cGVHD if they survived more than 90 days.
Statistical analysis
OS, TRM and relapse were calculated by the Kaplan --Meier method. Normality was checked before testing continuous variables in regression models and, if it was not met, covariates were log transformed or used as dichotomous variables, setting the threshold point at the median value. For univariate comparison of categorical variables, Fisher exact test or w 2 -test was used. One-way analysis of variance or non parametric tests (Kruskar --Wallis test) were used for comparing continuous variables, and corrections for multiple testing were done, as appropriate. Logistic and Cox proportional hazard regressions were used for performing multivariate analysis for aGVHD, cGVHD, survival, TRM and relapse. Factors showing a P-value o0.2 in univariate analysis were included in the final model to avoid simultaneous entering of correlated variables. The impact of cGVHD on survival, TRM and relapse was tested by time-dependent Cox model and by a landmark analysis as described by Anderson et al. 24 All calculations were made with IBM-SPSS Statistics (version 18, New York, NY, USA).
RESULTS
Cell grafts and hematological recovery
The median number of total nucleated cells, CD-34 þ and CD-3 þ cells infused were 2.77 Â 10 8 /kg, 1.41 Â 10 6 /kg and 24.3 Â 10 6 for patients receiving BM (group 1); 10 Â 10 8 /kg, 5 Â 10 6 /kg and 224 Â 10 6 /kg for those receiving PBSC (group 2); and 7.9 Â 10 8 /kg, 3.8 Â 10 6 /kg and 172 Â 10 6 /kg for patients (group 3) receiving PBSC þ ATG (Table 1) . Total nucleated cell, CD-34 þ and CD-3 þ cells were significantly lower in the group 1 in comparison with both groups 2 and 3, while comparing groups 2 and 3, significant differences were found on total nucleated cell count but not on CD-3 þ and CD-34 þ cells.
All patients engrafted and no rejection occurred. The median times to 0.5 Â 10 9 /L neutrophils were 18, 16 and 17 days in groups 1, 2 and 3, respectively; median times to 50 Â 10 9 /L All the pairwise comparisons showed a significant difference only for TNCs but neither for CD3+ or CD34+ cells. platelets were 27, 19 and 21 days in the same groups. No statistically significant differences were found between groups 2 and 3, either for neutrophil (P ¼ 0.138) or for platelet recovery (P ¼ 0.988). Instead, group 1 showed a statistically longer platelet recovery time compared with both PBSC groups. Neutrophil recovery in group 1 was significantly different from group 2 but not from group 3.
aGVHD and cGVHD Incidence of aGVHD and cGVHD is reported in Table 2 . In detail, severe aGVHD (grades III --IV) occurred in 14% of patients in group 1, 16% in group 2 and 10.5% in group 3. No significant differences were found either in grade III --IV aGVHD or in grade II --IV among the three groups (Table 2a) . Table 2b shows cGVHD occurrence; extensive cGVHD rate was higher with PBSC (group 2) than in the other two groups (P ¼ 0.03). Figure 1 shows the incidence of cGVHD by landmark analysis according to groups.
The variables tested in univariate analysis (Table 3) for aGVHD (grades II --IV and III --IV) and for cGVHD occurrence were groups, age, phase at transplant, intensity of conditioning (MA vs RIC), number of infused CD-34 þ and CD-3 þ cells, and gender.
Only gender was significantly associated with a higher probability (for males receiving a female graft) of developing severe aGVHD (P ¼ 0.026). Univariate analysis for cGVHD is shown in Table 3 . None of the previous factors was associated with increased cGVHD, except for group assignment.
Survival, TRM and relapse/progression Five-year survival probability was similar (P ¼ 0.79) in the three groups, as shown in Figure 2a . Moreover, 5-year TRM and relapse were similar in the three groups (Figures 2b and c) .
Univariate and multivariate analyses for TRM, relapse and OS are shown in Table 4 .
There was no significant difference among the three groups with respect to survival. Five-year OS probability was 53.2% in group 1, 49.3% in group 2 and 57.2% in group 3. Phase at transplant and gender significantly correlated with OS in multivariate analysis.
Five-year TRM probability was 21.2% for the the patients receiving PBSC with ATG (group 3), 34.6% for those receiving PBSC (group 2) and 36% for BM transplants (group 1). cGVHD was significantly associated with TRM.
Extensive cGVHD negatively affected TRM at a significant level, when analyzed both by a landmark analysis (P ¼ 0.01) and by time-dependent Cox model (P ¼ 0.0001).
From the multivariate analysis (Table 4) , age and cGVHD (extensive vs limited vs no cGVHD) were both significant prognostic factors for TRM.
The probability of relapse/progression at 5 years was 27.3%, 38.7% and 34.5% in groups 1, 2 and 3, respectively.
cGVHD was partially associated with relapse, when analyzed both by landmark analysis (Figure 3 , P ¼ 0.07) and also univariately by a time-dependent Cox model (P ¼ 0.059). Limited cGVHD seemed to be tendentially protective for relapse, without increasing TRM.
Significant prognostic factors for relapse were phase at transplant and MA vs RIC, while cGVHD resulted marginally significant (P ¼ 0.059, Table 4) .
No CMV diseases occurred in the three groups. We also did not observe any EBV --PTLD (EBV-related post-transplant lympho proliferative disorders) or EBV --DNAemia positivity in the first 6 months after transplant.
DISCUSSION
In the past 15 years, the use of peripheral blood as a source of hemopoietic stem cells for allogeneic transplantation has Among the potential problems associated with PBSC, it has become increasingly evident that although aGVHD is generally not increased, cGVHD occurs with a higher frequency as compared with BM. 5 --19 In this paper, we retrospectively analyze a large cohort of 245 consecutive adult patients undergoing allogeneic transplant for hematological malignancies from fully HLA-matched sibling donors, at a single Institution, with BM (group 1) or PBSC (group 2) or PBSC þ ATG (group 3) and receiving the same GVHD prophylaxis, that is, CsA and MTX. The three groups were similar according to the disease phase at transplant, although the distribution of diseases was heterogeneous.
TRM, relapse and survival were similar among the three groups: aGVHD in group 3 (PBSC þ ATG) tended to be lower---although not at a statistical level---than in group 2 (PBSC). Hematological recovery was significantly longer in BM than in PBSC recipients; it was also slightly delayed (by 1 day for neutrophils and 2 days for platelets) in group 3 (PBSC þ ATG), in line with the results from a randomized study in unrelated transplants. 22 We found that extensive cGVHD was less frequent when ATG was added to PBSC, as widely reported in the literature 23,26 --29 and also recently demonstrated by the randomized study by Finke et al. 22 (in unrelated 8/8 matched transplants, mainly with PBSC). An important finding of our study is that cGVHD, when analyzed on the whole patient population, was significantly associated with a higher TRM; however, we did not observe a significant reduction of TRM in the group 3 (PBSC þ ATG), despite the occurrence of less extensive cGVHD. Reasons such as underpowered sample size, the shorter follow-up of patients in group 3 and the occurrence of late events, beyond five years, can explain such discrepant findings. cGVHD is a time-dependent variable; it takes time to develop and it takes much more time to impact TRM and hence survival. This has been observed in several instances, such as the prospective randomized EBMT study, 6,15 the randomized French study, 8,13 the comparative Seattle study, 5,11 the EBMT/CIBMTR comparative study and 9,14 the Brazilian study; 7,12 in all of them only subsequent follow-up analyses showed the progressive, significant increase of cGVHD, particularly of the extensive type, in recipients of PBSC transplants, showing that the early advantages were not sustained with longer follow-up. With regard to cGHVD we also confirm that it occurrred with a substantially high rate (78/125 evaluable patients, 62%) and the extensive type was the commonest form (55/75, 73%) when PBSCs were used. In addition, limited cGVHD had no significant impact on TRM and instead tended to be protective of disease recurrence, as shown in Figure 3 . These findings are in agreement with most of the published data. As limited cGVHD still exerts anti-neoplastic activity 30 with very little impairment of patients quality of life, several strategies to intensify GVHD prophylaxis have been reported, such as the administration of the full dose (four doses) of MTX, 31 the substitution of mycophenolate mofetil for MTX, 32 T-cell depletion and/or CD34 selection, 33 ,34 a longer period of CsA administration post transplant, 35 the use of additional drugs, such as rapamycin, 36 or polyclonal anti-lymphocyte antibodies. 37 Recently, the combination of tacrolimus and mycophenolate mofetil or MTX has been reported, 38, 39 with promising results in the setting of non-MA transplants. We have used ATG-F in the setting of unrelated transplants since 1995 and then extended it to PBSC family transplants after observing high rates of extensive cGVHD; the results were satisfactory, with a substantial reduction of severe cGVHD. 23 Our present series confirms those findings. A concern associated with anti-thymocyte globulins is the possible increase in relapse; this has been observed in a few studies 40, 41 Intensification of GVHD prophylaxis in PBSC sibling allotransplants F Bonifazi et al but not in other studies. 22, 26, 27 Moreover, the use of varying doses and different brands of ATGs, which display very different antibody specificities and immunological effects, 42 may have an influence on the risk of relapse. No clear statement can be drawn about the dose of ATG-F, in particular in the setting of HLAidentical sibling. We observed a reduction of GVHD also with doses that can be defined 'low' compared with those used by other authors. 22, 26 We have used the rabbit preparation raised against the lymphoblastoid Jurkatt cell line, the same used in the prospective, randomized trial published by Finke et al.; 22 we did not find an increase of relapse, similar to that study. Our present analysis shows that the relapse rate was similar in the three study groups; when relapse was analyzed in multivariate analysis, cGHVD (Table 4) tended to be associated with less relapse; in detail (Figure 3b) , we found that patients with limited GVHD had the lowest relapse rate, compared with severe GVHD or no GVHD. Relapse was also significantly associated with the intensity of the preparative regimen, as expected; 43 however, the most relevant factor associated with relapse was the phase of the disease at transplant. Anyway, a limit of our study can be represented by the heterogeneous disease composition of the groups, even though the phases (advanced vs early) were similar in the three groups. As shown in Table 1 , acute leukemias were underrepresented in group 3 (PBSC þ ATG-F), thus obscuring a possible impact of ATG on disease recurrence. Relapse, more than TRM, is a diseaseassociated factor and should be analyzed in the context of a single disease. A subgroup analysis according to the intensity of conditioning was not performed because the proportion of patients receiving a RIC transplant was too small to allow an enough powered comparison.
Our data show that PBSC þ ATG gives results similar to BM with respect to cGVHD, TRM, relapse and OS. Results from the long-term follow-up of the EBMT randomized study published by Friedrichs et al. 15 do not conclusively support the return to BM transplantation in all cases; however, in good-risk patients with acute leukemias, OS and leukemia-free survival (LFS) at 10 years tended to be superior with BM over PBSC, although not at a level of statistical significance. That study reports that the vastly increased severe cGVHD, requiring prolonged immunosuppression, observed in patients receiving PBSC, has no impact on TRM and survival; such positive and reassuring findings, which perhaps reflect better treatment of cGVHD, should be confirmed by other randomized studies. Decision analysis of PBSC vs BM by Pidala et al. confirmed a higher rate of cGVHD after PBSC transplants without a negative Intensification of GVHD prophylaxis in PBSC sibling allotransplants F Bonifazi et al impact on survival, leading to a gain of 7 months in life expectancy compared with BM transplants, even after adjustment for quality of life; they conclude that PBSC is the preferred source, except for the conditions in which the 1-year relapse probability is o5%, where BM should be used instead. 21 These two latter studies support the concept that the best source of hematopoietic stem cells could be different for different patient groups.
As ATG-F in PBSC transplants determines a lower cGVHD rate, similar to that of BM and does not seem to clearly increase the risk of disease recurrence, we suggest that it could be used in the HLA-identical sibling setting as well, at least after MA conditioning. However, even if the results of the present retrospective analysis confirm the same benefit of intensification of GVHD prophylaxis already observed in the unrelated setting, 22 it should be underlined that these findings have to be confirmed by ongoing prospective randomized studies. 
